FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022

MANNKIND CORP

Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.
Manufacturing of Tyvaso DPI underway at MannKind's Connecticut facility; product availability expected in June 2022.
Commercial supply agreement with United Therapeutics runs through 2031; initially signed in August 2021.
Tyvaso DPI uses dry powder formulation and Dreamboat inhaler technology from Afrezza; convenient alternative to liquid nebulization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.